2 March 2011 Last updated at 23:22 GMT
Ibuprofen 'cuts Parkinson's disease risk'
By Michelle Roberts Health reporter, BBC News
People who take ibuprofen on a regular basis have a lower risk of developing Parkinson's disease, research suggests.
The drug is commonly used to ease aches and pains but US research, in Neurology journal, found it had an added benefit.
In studies of more than 135,000 men and women regular users of ibuprofen were 40% less likely to develop Parkinson's.
However, experts say it is too early to say whether the benefits of taking the drug outweigh the risk of side effects such as gastrointestinal bleeding.
Scientists have suspected for some time that anti-inflammatory drugs might help buffer against the disease but it was unclear which ones in the family of non-steroidal anti-inflammatory drugs or NSAIDs conferred a benefit.
This most recent study suggests it is ibuprofen alone that has an effect.
But like all NSAIDs, ibuprofen can cause worrying side effects, like an increased risk of gastrointestinal bleeding.
A recent study also linked ibuprofen taken daily for some years to a small increased risk of heart attack and stroke.
The findings relate to non-steroidal anti-inflammatory drugs like ibuprofen prescribed long-term to treat painful conditions such as arthritis.
For this reason experts say more work is needed to determine whether the benefits of taking the drug more often would outweigh any risks.
If it did, it could offer a new way of managing this incurable neurological condition.
Lead researcher Professor Alberto Ascherio, of the Harvard School of Public Health, said: "There is no cure for Parkinson's disease, so the possibility that ibuprofen, an existing and relatively non-toxic drug, could help protect against the disease is captivating."
In his study, funded by the Michael J Fox Foundation, men and women who used ibuprofen two or more times a week reduced their risk of Parkinson's disease by more than a third compared with those who regularly used aspirin, acetaminophen, or other NSAIDs.
Dr Kieran Breen, director of Research and Development at Parkinson's UK, said it was difficult to know exactly what effect ibuprofen might be having on the death of nerve cells in the brain, and how it might affect whether somebody will get Parkinson's. But based on the findings of this latest study, he said there would seem to be an interesting link.
He said: "We know that inflammatory changes in the brain may be involved in the death of nerve cells which cause Parkinson's, particularly in the early stages of the condition.
"We are currently funding research into this area ourselves at the University of Oxford."
As to why ibuprofen alone might have the desired effect, the US researchers say it could be down to the fact that this drug has a specific role in blocking a biological pathway of cell damage and death.
Use of ibuprofen and risk of Parkinson disease
1. Xiang Gao, MD, PhD,
2. Honglei Chen, MD, PhD,
3. Michael A. Schwarzschild, MD, PhD and
4. Alberto Ascherio, MD, DrPH
+ Author Affiliations
From the Channing Laboratory (X.G., A.A.), Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston; Departments of Nutrition (X.G., A.A.) and Epidemiology (A.A.), Harvard University School of Public Health, Boston, MA; Epidemiology Branch (H.C.), National Institute of Environmental Health Sciences, Research Triangle Park, NC; and Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston.
1. Address correspondence and reprint requests to Dr. Xiang Gao, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, 181 Longwood Ave., Boston, MA 02115 firstname.lastname@example.org
Background: Neuroinflammation may contribute to the pathogenesis of Parkinson disease (PD). Use of nonsteroidal anti-inflammatory drugs (NSAID) in general, and possibly ibuprofen in particular, has been shown to be related to lower PD risk in previous epidemiologic studies.
Methods: We prospectively examined whether use of ibuprofen or other NSAIDs is associated with lower PD risk among 136,197 participants in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) free of PD at baseline (1998 for NHS and 2000 for HPFS). NSAIDs use was assessed via questionnaire. Results were combined in a meta-analysis with those of published prospective investigations.
Results: We identified 291 incident PD cases during 6 years of follow-up. Users of ibuprofen had a significantly lower PD risk than nonusers (relative risk [RR], adjusted for age, smoking, caffeine, and other covariates = 0.62; 95% confidence interval [CI] 0.42--0.93; p = 0.02). There was a dose--response relationship between tablets of ibuprofen taken per week and PD risk (p trend = 0.01). In contrast, PD risk was not significantly related to use of aspirin (RR = 0.99; 95% CI 0.78--1.26), other NSAIDs (RR = 1.26; 95% CI 0.86--1.84), or acetaminophen (RR = 0.86; 95% CI 0.62--1.18). Similar results were obtained in the meta-analyses: the pooled RR was 0.73 (95% CI 0.63--0.85; p < 0.0001) for ibuprofen use, whereas use of other types of analgesics was not associated with lower PD risk.
Conclusions: The association between use of ibuprofen and lower PD risks, not shared by other NSAIDs or acetaminophen, suggests ibuprofen should be further investigated as a potential neuroprotective agent against PD.
|<< 前記事(2011/03/02)||ブログのトップへ||後記事(2011/03/04) >>|
|<< 前記事(2011/03/02)||ブログのトップへ||後記事(2011/03/04) >>|